Tech Company Financing Transactions
Appili Therapeutics Funding Round
Appili Therapeutics, based in Halifax NS, secured $7.3 million in funding from United States Air Force Academy.
Transaction Overview
Company Name
Announced On
5/8/2023
Transaction Type
Venture Equity
Amount
$7,300,000
Round
Undisclosed
Investors
United States Air Force Academy (Lead Investor)
Proceeds Purpose
This fund will be used to kick-off ATI-1701 early-stage development and regulatory activities. As the initial activities progress, Appili will be engaging USAFA for additional tranches of funding to continue development through IND. ATI-1701, our biodefense vaccine candidate, is the Company's potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1344 Summer St. 21
Halifax NS, B3H 0A8
Canada
Halifax NS, B3H 0A8
Canada
Phone
Website
Email Address
Overview
Appili Therapeutics is developing novel approaches to lead the fight against infectious disease. Despite numerous achievements in the development of anti-infectives, infectious disease remains the leading cause of death worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Sullivan
Chief Financial Officer
Kimberly Stephens
VP - Bus. Development
Armand Balboni
VP - Manufacturing
Myriam Triest
Browse more venture capital transactions:
Prev: 5/8/2023: Pudu Robotics venture capital transaction
Next: 5/8/2023: Slick venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs